Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 157


Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.

Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, Chew A, Zhao Y, Levine BL, Albelda SM, Kalos M, June CH.

Cancer Immunol Res. 2014 Feb;2(2):112-20. doi: 10.1158/2326-6066.CIR-13-0170. Erratum in: Cancer Immunol Res. 2015 Feb;3(2):217.


T cells expressing chimeric antigen receptors can cause anaphylaxis in humans.

Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, Zhao Y, Kalos M, June CH.

Cancer Immunol Res. 2013 Jul;1(1):26-31. doi: 10.1158/2326-6066.CIR-13-0006. Epub 2013 Apr 7.


Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.

Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J, Jones DR, Sadelain M.

Sci Transl Med. 2014 Nov 5;6(261):261ra151. doi: 10.1126/scitranslmed.3010162.


Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy.

O'Hara M, Stashwick C, Haas AR, Tanyi JL.

Immunotherapy. 2016;8(4):449-60. doi: 10.2217/imt.16.4. Review.


Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor.

Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, Chew A, Carroll RG, Scholler J, Levine BL, Albelda SM, June CH.

Cancer Res. 2010 Nov 15;70(22):9053-61. doi: 10.1158/0008-5472.CAN-10-2880. Epub 2010 Oct 5.


Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors.

Moon EK, Wang LC, Dolfi DV, Wilson CB, Ranganathan R, Sun J, Kapoor V, Scholler J, Puré E, Milone MC, June CH, Riley JL, Wherry EJ, Albelda SM.

Clin Cancer Res. 2014 Aug 15;20(16):4262-73. doi: 10.1158/1078-0432.CCR-13-2627. Epub 2014 Jun 11.


A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer.

Abate-Daga D, Lagisetty KH, Tran E, Zheng Z, Gattinoni L, Yu Z, Burns WR, Miermont AM, Teper Y, Rudloff U, Restifo NP, Feldman SA, Rosenberg SA, Morgan RA.

Hum Gene Ther. 2014 Dec;25(12):1003-12. doi: 10.1089/hum.2013.209.


Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells.

Schuberth PC, Hagedorn C, Jensen SM, Gulati P, van den Broek M, Mischo A, Soltermann A, Jüngel A, Marroquin Belaunzaran O, Stahel R, Renner C, Petrausch U.

J Transl Med. 2013 Aug 12;11:187. doi: 10.1186/1479-5876-11-187.


Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.

Hillerdal V, Essand M.

BioDrugs. 2015 Apr;29(2):75-89. doi: 10.1007/s40259-015-0122-9. Review.


Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice.

Hillerdal V, Ramachandran M, Leja J, Essand M.

BMC Cancer. 2014 Jan 18;14:30. doi: 10.1186/1471-2407-14-30.


Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo.

Lanitis E, Poussin M, Klattenhoff AW, Song D, Sandaltzopoulos R, June CH, Powell DJ Jr.

Cancer Immunol Res. 2013 Jul;1(1):43-53.


Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1).

Petrausch U, Schuberth PC, Hagedorn C, Soltermann A, Tomaszek S, Stahel R, Weder W, Renner C.

BMC Cancer. 2012 Dec 22;12:615. doi: 10.1186/1471-2407-12-615.


Treatment of advanced leukemia in mice with mRNA engineered T cells.

Barrett DM, Zhao Y, Liu X, Jiang S, Carpenito C, Kalos M, Carroll RG, June CH, Grupp SA.

Hum Gene Ther. 2011 Dec;22(12):1575-86. doi: 10.1089/hum.2011.070. Epub 2011 Sep 23.


Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor.

Lanitis E, Poussin M, Hagemann IS, Coukos G, Sandaltzopoulos R, Scholler N, Powell DJ Jr.

Mol Ther. 2012 Mar;20(3):633-43. doi: 10.1038/mt.2011.256. Epub 2011 Nov 29.


Engineered T cells for pancreatic cancer treatment.

Katari UL, Keirnan JM, Worth AC, Hodges SE, Leen AM, Fisher WE, Vera JF.

HPB (Oxford). 2011 Sep;13(9):643-50. doi: 10.1111/j.1477-2574.2011.00344.x. Epub 2011 Jul 20.


Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies.

Rodgers DT, Mazagova M, Hampton EN, Cao Y, Ramadoss NS, Hardy IR, Schulman A, Du J, Wang F, Singer O, Ma J, Nunez V, Shen J, Woods AK, Wright TM, Schultz PG, Kim CH, Young TS.

Proc Natl Acad Sci U S A. 2016 Jan 26;113(4):E459-68. doi: 10.1073/pnas.1524155113. Epub 2016 Jan 12.


In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB).

Song DG, Ye Q, Carpenito C, Poussin M, Wang LP, Ji C, Figini M, June CH, Coukos G, Powell DJ Jr.

Cancer Res. 2011 Jul 1;71(13):4617-27. doi: 10.1158/0008-5472.CAN-11-0422. Epub 2011 May 5.


Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor.

Moon EK, Carpenito C, Sun J, Wang LC, Kapoor V, Predina J, Powell DJ Jr, Riley JL, June CH, Albelda SM.

Clin Cancer Res. 2011 Jul 15;17(14):4719-30. doi: 10.1158/1078-0432.CCR-11-0351. Epub 2011 May 24.


Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors.

Morello A, Sadelain M, Adusumilli PS.

Cancer Discov. 2016 Feb;6(2):133-46. doi: 10.1158/2159-8290.CD-15-0583. Epub 2015 Oct 26. Review.


Clinical Evaluation of ErbB-Targeted CAR T-Cells, Following Intracavity Delivery in Patients with ErbB-Expressing Solid Tumors.

Papa S, van Schalkwyk M, Maher J.

Methods Mol Biol. 2015;1317:365-82. doi: 10.1007/978-1-4939-2727-2_21.


Supplemental Content

Support Center